From the floor in Tianjin: 7 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Trial design
Page 31 of 32 of this archive, newest first.
TRIUMPH-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURMOUNT-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
From the floor in Zhuhai: 18 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Reading the semaglutide composition data without the press release
The composition data comes from imaging substudies enrolling a few score participants at selected sites. It is the best evidence available and it is thin.
What happens when the drug is taken away: three randomised answers
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
From the floor in Changsha: 12 posters, one theme
Reported from the sessions, and from the two hours afterwards.
A guide to the results that will resolve themselves
Three different explanations for the same abnormal number, and how to tell them apart.
Side effects, cost, supply, target: four reasons with four trajectories
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
Bone density during rapid weight loss: what is known, which is less than you would hope
Weight loss reduces bone mineral density at load-bearing sites. Whether that translates into fractures in this population is unmeasured.
SURMOUNT-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURPASS-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURMOUNT-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
STEP 2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What the older diet-and-exercise trials found in the hip
A plausible mechanism, a measurable change, and no outcome data. This is what an open question looks like.
SURMOUNT-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
REWIND extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.